LOCALLY ADVANCED SOLID TUMOR
Clinical trials for LOCALLY ADVANCED SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED SOLID TUMOR trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink tumors. All participants receive the drug by injecti…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
New pill targets cancers with missing gene in early trial
Disease control Recruiting nowThis study tests a new oral drug, TNG462, in people with advanced solid tumors that lack the MTAP gene. The goal is to find a safe dose and see if it can shrink tumors, alone or with another drug. Up to 225 adults with specific tumor types will take part in this early-phase trial…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for rare cancer: targeted drug shrinks tumors in early trials
Disease control Recruiting nowThis study tests a new drug called zidesamtinib (NVL-520) in people with advanced lung cancer or other solid tumors that have a specific genetic change (ROS1-positive). The goal is to find the best dose and see how well it shrinks tumors. About 359 adults will take part. The drug…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New ALK blocker NVL-655 enters trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called NVL-655 in people with advanced ALK-positive lung cancer and other solid tumors. The goal is to find the best dose and see how well it shrinks tumors. About 840 participants will take the pill daily, and researchers will monitor side effects and…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New pill targets Hard-to-Treat lung cancer mutation
Disease control Recruiting nowThis early-stage study tests an experimental pill called NVL-330 in about 200 adults with advanced lung cancer that has a specific change in the HER2 gene. The main goals are to find a safe dose and see if the drug can shrink tumors or slow the cancer. Participants must have trie…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Nanoparticle radiation therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called 177Lu-SN201 for people with advanced solid tumors that have not responded to standard therapies. The treatment uses tiny particles that deliver radiation directly to tumors. The goal is to find the safest dose and see if it can shrink tumor…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Spago Nanomedical AB • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug FOG-001 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New cancer antibody enters human testing
Disease control Recruiting nowThis is the first study in people testing a new antibody drug called NTX-1088, which targets a protein found on many cancer cells. The trial will test the safety of NTX-1088 given alone and in combination with an existing immunotherapy drug (pembrolizumab) in 90 patients with adv…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1 • Sponsor: Nectin Therapeutics Ltd • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New scan could reveal how well immunotherapy works in real time
Diagnosis Recruiting nowThis study tests a special imaging agent (89Zr-DF-Crefmirlimab) that helps PET scans show where immune cells called CD8 T-cells are in the body. About 30 adults with advanced solid tumors will receive this agent before and during standard immunotherapy. The goal is to see if the …
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE2 • Sponsor: University Medical Center Groningen • Aim: Diagnosis
Last updated May 12, 2026 13:39 UTC
-
New lattice radiation aims to shrink bulky tumors
Symptom relief Recruiting nowThis study tests a new type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better and with fewer side effects than standard radiation. About 37 adults with advanced solid tumors will receive this treatme…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE2 • Sponsor: University of Cincinnati • Aim: Symptom relief
Last updated May 17, 2026 00:29 UTC
-
Cream may soothe rash caused by cancer drugs
Symptom relief Recruiting nowThis study tests if a tretinoin cream can help reduce the acne-like rash that some cancer patients get from their treatment. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo to the other. Researchers will compare the rash sev…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Apr 30, 2026 15:50 UTC